REVLIMID® (lenalidomide) is indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1–risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

Consider REVLIMID first for lower-risk del 5q MDS.*

Learn about how REVLIMID works.

Learn More

*Transfusion dependent.

Female Hypothetical REVLIMD Patient®
Female Hypothetical REVLIMD Patient®

Not an actual patient.

HCP and Patient Icon

Resources and tools for healthcare providers.

Access HCP Tools

Can you cut transfusion dependence out of del 5q MDS?

Learn more about REVLIMID clinical trial results for del 5q MDS.

Explore Efficacy